InhaleRx Limited is an Australia-based clinical stage drug development company. The...InhaleRx Limited is an Australia-based clinical stage drug development company. The Company is focused on developing onset, inhaled therapies to address unmet medical needs in pain management and mental health sectors. The Company is focused on the development of IRX211 to treat Breakthrough Cancer Pain (BTcP), and IRX-616a to treat panic disorders. The Company’s operates through single segment that is the development of medical technologies. Its IRX-211 focuses on the management of BTcP with non-opioid, onset inhaled therapy. The Phase I clinical trials for IRX-211 have been completed. Its IRX-616a is an approved inhaled medication for panic disorder, offering a novel treatment avenue. It holds a patent that has been approved, and provisional patents have been lodged. The Company has identified some composition properties in the way the IRX211 drug device has performed and focused on developing resulting novel intellectual property in consultation with its patent attorneys.More
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.